Mobile

A 14 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in an environmental exposition unit (Vienna Challenge Chamber) in sub...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-005340-12

A 14 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in an environmental exposition unit (Vienna Challenge Chamber) in subjects with seasonal allergic rhinitis (SAR)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Investigate effect of repeat intranasal doses of GSK256066 vs. placebo on nasal symptoms of allergic rhinitis provoked by spending 6h in the Vienna Challenge Chamber after dosing on Day 14

Critère d'inclusion

  • Seasonal Allergic Rhinitis

Liens